Please select your location and reference genome:
Congenica selected for final phase of Instand-NGS4P
precision oncology

Congenica selected for final phase of Instand-NGS4P

5/21/2024    |    0 min read

Cambridge, United Kingdom – 21 May, 2024 – Congenica, a UK-based digital health company specialising in innovative software and solutions for genomic data analysis and interpretation, is pleased to announce its selection for the third phase of a contract to develop standardised Next-Generation Sequencing (NGS) workflows in oncology.


The European Union Horizon 2020 co-funded project, ‘INtegrated and STANDardized NGS workflows FOR Personalized therapy’ (Instand-NGS4P), has been set up to support the development of innovative integrated and standardised Next Generation Sequencing (NGS) workflows to guide therapy decisions and provide clinical decision support at bedside for the benefit of patient care.


As growing patient numbers and increasing clinical needs drive the adoption of cancer genomics into routine cancer care, the provision of accurate, timely and individualised therapeutic recommendations is crucial. To help pave the way for cost-effective integration of Precision Oncology into routine clinical care, Congenica has developed a fully automated data analysis and reporting platform that enables evidence-based interpretation of NGS data with focus on actionable insights for rapid treatment decisions.


Throughout this last phase of the Instand-NGS4P project, Congenica’s product will now be installed and tested at various sites across Europe over the next 12 months. During this time, consortium members will focus specifically on the accuracy, usability and interoperability of the product.


Alistair Johnson, Chief Commercial Officer at Congenica, said: “We are delighted to have been selected for this final phase of the Instand-NGS4P project. With a commitment to global quality standards, our fully automated, integrated and scalable end-to-end solution will help drive Precision Oncology, enable healthcare providers deliver the highest quality care to their patients and provide patients with the utmost benefit of personalised healthcare.” 

Congenica was selected in March 2024 from several highly competitive applications, which were assessed in a multi-step peer-reviewed process. Phase 3 will focus on the evaluation of the product, which was developed during Phase 2, and is scheduled for completion in May 2025.



About INtegrated and STANDardized NGS workflows FOR Personalized therapy (INSTAND-NGS4P, Grant No. 874719)

A Pre-Procurement Project for improving cancer patients’ benefit from Next Generation Sequencing (NGS) by developing an integrated and standardised NGS workflow and integrating information from cancer gene testing, pharmacogenetics testing and e-medication in proper presentation to medical doctors for supporting therapy decision making at bedside. This 65-month H2020 project started in January 2020.

Media Contacts

Heike Fiegler, Director of Strategic Sales & Marketing at Congenica